NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 9% mid-day following the company’s comments regarding the recent FDA approvals for new drugs for the treatment of acute myeloid leukemia (AML). The company’s drug candidate, Annamycin, is currently being evaluated for the treatment of relapsed or refractory AML. “While these new drugs make valuable incremental improvements in AML therapy, most AML patients will still fail to respond to (or relapse from) initial therapy; therefore, our initial clinical development plan will attempt to address the significant unmet need of patients who relapse from, or are refractory to, initial therapy. We also believe that, if Annamycin can demonstrate superior efficacy and safety to the current standard of care, the drug may be able to fill major areas for first-line AML treatment. In the meantime, these transactions serve to remind us of the opportunity for our company if Annamycin shows significant activity in our planned clinical trials,” Moleculin CEO Walter Klemp stated in the news release.

To view the full press release, visit:

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at MD Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. Moleculin also has two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. The other portfolio targets the metabolism of tumors. For more information about the company, please visit

More from NetworkNewsBreaks

Patriot One Technologies’ (TSX.V: PAT) (OTCQB: PTOTF) PATSCAN CMR Attains Milestone in Certification Pathway

Rennova Health, Inc. (NASDAQ: RNVA) Opens Big South Fork Medical Center

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Trading Volume Surges on Positive CLR 131 Report

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s